Key Takeaways
- • 137 Ventures' 2014 fund achieved an 8.2x return on its SpaceX investment after distributing $2.5 billion in shares, demonstrating exceptional outperformance from a $137 million initial fund deployment across roughly two decades of follow-on rounds since 2010.
- • The firm closed $700 million across two new growth-stage funds, elevating total assets under management to over $15 billion, with SpaceX, Anduril, Cognition, and Hadrian anchoring its expanded portfolio.
- • 137 Ventures now owns over 1% of SpaceX following the company's valuation milestone, reflecting concentrated pre-IPO exposure accumulated through patient capital deployment across approximately two dozen funding rounds.
- • The firm's strategy of backing technology companies across their entire private growth lifecycle—from expansion rounds through pre-IPO stages—has generated outsized returns, positioning 137 Ventures as a leading growth-stage venture investor with significant dry powder for future deployment.
Summary
137 Ventures has delivered exceptional returns to its investors, with the San Francisco-based growth-stage venture firm's 2014 fund surging to an 8.2x multiple following a massive distribution of SpaceX shares valued at $2.5 billion. The fund, which began with $137 million in committed capital, has benefited from patient capital deployment and sustained conviction in SpaceX across roughly two dozen funding rounds dating to 2010, when the rocket company was valued at approximately $1 billion.
The firm's strong performance has positioned it for significant capital raises. In its latest fundraising cycle, 137 Ventures closed $700 million across two new growth-stage funds, bringing total assets under management to over $15 billion. This capital infusion reflects institutional confidence in the firm's investment thesis and track record, particularly given its track record of sustained exposure to transformative technology companies.
Beyond SpaceX, 137 Ventures' portfolio now includes high-conviction bets on Anduril, Cognition, Hadrian, Ramp, and Gusto—companies operating across defense technology, artificial intelligence, manufacturing, and financial operations. Founded in 2010 by Justin Fishner-Wolfson and Alexander Jacobson, the firm specializes in backing technology companies across their entire private growth lifecycle, from expansion rounds through pre-IPO stages. This strategy has demonstrated particular efficacy in capturing value creation across extended private holding periods.
The firm's current ownership stake in SpaceX exceeds 1% following the company's rise in valuation, representing concentrated pre-IPO exposure that has generated material returns for its investor base. The SpaceX distribution and broader fund performance underscore the potential of long-term, patient venture capital strategies deployed into transformative technology platforms, though such concentration also carries inherent risk for limited partners seeking diversified exposure.
The firm's strong performance has positioned it for significant capital raises. In its latest fundraising cycle, 137 Ventures closed $700 million across two new growth-stage funds, bringing total assets under management to over $15 billion. This capital infusion reflects institutional confidence in the firm's investment thesis and track record, particularly given its track record of sustained exposure to transformative technology companies.
Beyond SpaceX, 137 Ventures' portfolio now includes high-conviction bets on Anduril, Cognition, Hadrian, Ramp, and Gusto—companies operating across defense technology, artificial intelligence, manufacturing, and financial operations. Founded in 2010 by Justin Fishner-Wolfson and Alexander Jacobson, the firm specializes in backing technology companies across their entire private growth lifecycle, from expansion rounds through pre-IPO stages. This strategy has demonstrated particular efficacy in capturing value creation across extended private holding periods.
The firm's current ownership stake in SpaceX exceeds 1% following the company's rise in valuation, representing concentrated pre-IPO exposure that has generated material returns for its investor base. The SpaceX distribution and broader fund performance underscore the potential of long-term, patient venture capital strategies deployed into transformative technology platforms, though such concentration also carries inherent risk for limited partners seeking diversified exposure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.